Novartis announced that pelacarsen, its experimental heart disease drug, did not meet its primary endpoint in the Phase 3 HORIZON trial. This outcome is a significant setback for the Swiss pharmaceutical giant, which had high hopes for pelacarsen as a potential blockbuster drug. The drug was designed to reduce cardiovascular events in patients with elevated lipoprotein(a) or Lp(a), a genetic risk factor for heart disease.
Analysts had estimated pelacarsen, along with two other experimental drugs, could generate over $10 billion in peak annual sales. This was crucial for Novartis as it faces upcoming patent expirations for top-selling drugs like Cosentyx and Kisqali around the end of the decade, and its heart drug Entresto is already contending with generic competition. The failure of pelacarsen to demonstrate a significant benefit in reducing cardiovascular events means Novartis will need to rely more heavily on its remaining pipeline assets to drive future growth.
The news has sparked concerns among investors and analysts, as much of Novartis's premium valuation was predicated on the success of these late-stage experimental drugs. Some analysts had previously warned that the market could be unforgiving if clinical trials did not meet expectations. The failure of pelacarsen raises questions about the overall strategy for targeting Lp(a) and its impact on cardiovascular outcomes, potentially shifting the focus to other mechanisms or patient segments for future drug development in this area.
